Yifei Wang

Serum miRNA expression profile as a prognostic biomarker of stage II/III colorectal adenocarcinoma.

STAT1-mediated inhibition of FOXM1 enhances gemcitabine sensitivity in pancreatic cancer.

Delta HU is a potential marker to predict chemotherapy response for unresectable pancreatic ductal adenocarcinoma.

PERK-eIF2α-ERK1/2 axis drives mesenchymal-endothelial transition of cancer-associated fibroblasts in pancreatic cancer.

High GNG4 expression is associated with poor prognosis in patients with lung adenocarcinoma.

Serum IL-35 levels is a new candidate biomarker of cancer-related cachexia in stage IV non-small cell lung cancer.

Genome-wide CRISPR screen identifies MTA3 as an inducer of gemcitabine resistance in pancreatic ductal adenocarcinoma.

MiR-125b-5p modulates the function of regulatory T cells in tumor microenvironment by targeting TNFR2.

SDCBP promotes pancreatic cancer progression by preventing YAP1 from β-TrCP-mediated proteasomal degradation.

Irbesartan overcomes gemcitabine resistance in pancreatic cancer by suppressing stemness and iron metabolism via inhibition of the Hippo/YAP1/c-Jun axis.

Targeting ESE3/EHF With Nifurtimox Inhibits CXCR2 Neutrophil Infiltration and Overcomes Pancreatic Cancer Resistance to Chemotherapy and Immunotherapy.

The ATF4-RPS19BP1 axis modulates ribosome biogenesis to promote erythropoiesis.

CD64 fibroblast-targeted vilanterol and a STING agonist augment CLDN18.2 BiTEs efficacy against pancreatic cancer by reducing desmoplasia and enriching stem-like CD8 T cells.

Survival outcomes of adjuvant chemotherapy in patients with stage I pancreatic cancer stratified by pathologic risk.

Computational modeling of mast cell tryptase family informs selective inhibitor development.

The nuclear condensates of ESE3/EHF induce cellular senescence without the associated inflammatory secretory phenotype in pancreatic ductal adenocarcinoma.